Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent

被引：7

作者：

Rastogi, Anjay ^{[1
,2
]}

Hanna, Ramy M. ^{[3
]}

Mkrttchyan, Anita ^{[1
,2
]}

Khalid, Maham ^{[1
,2
]}

Yaqoob, Sinan ^{[1
,2
]}

Shaffer, Kelly ^{[4
]}

Dhawan, Puneet ^{[5
]}

Nobakht, Niloofar ^{[1
,2
]}

Kamgar, Mohammad ^{[1
,2
]}

Goshtaseb, Ray ^{[1
,2
]}

Sarmosyan, Kristine ^{[1
,2
]}

Gnarini, Mariarosaria ^{[4
]}

Wassef, Olivia ^{[4
]}

Lerma, Edgar ^{[6
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, CORE Kidney Hlth Program, Los Angeles, CA 90095 USA

[2] UCLA Hlth, Div Nephrol, Dept Med, Los Angeles, CA USA

[3] Univ Calif Irvine, Dept Med, Med Ctr, Div Nephrol, Irvine, CA 92717 USA

[4] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA

[5] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiothorac Surg, Los Angeles, CA 90095 USA

[6] Univ Illinois, Div Nephrol, Chicago, IL USA

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2021年 / 14卷 / 09期

关键词：

Hyperkalemia; Chronic Kidney Disease (CKD); End Stage Kidney Disease (ESKD); Sodium Zirconium Cyclosilicate (SZC); Patiromer Calcium; Sodium Polystyrene Sulfonate (SPS); Randomized Clinical Trial (Rct); End Of Treatment (EOT); HEART-FAILURE PATIENTS; SERUM POTASSIUM; POLYSTYRENE SULFONATE; EXCHANGE RESIN; PATIROMER; ALDOSTERONE; PREVENTION; MORTALITY; EFFICACY; SORBITOL;

D O I：

10.1080/17512433.2021.1932460

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction Hyperkalemia is a common finding in patients with advanced kidney disease for multiple reasons. Renin-Angiotensin-Aldosterone-System Inhibitors (RAASi) that are indicated for slowing down progression of kidney disease are often associated with hyperkalemia which becomes a limiting factor in their use and titration to the maximum dose. Having a safe, effective, tolerable, and affordable potassium binder can help optimize RAAS inhibition in the setting of kidney disease. Areas covered Although sodium polystyrene sulfonate has been a mainstay of acute management of hyperkalemia for decades, evidence regarding its efficacy is limited, and its chronic use is not routinely recommended for concerns regarding toxicity. The concern of gastrointestinal (GI) adverse effects with sodium polystyrene sulfonate has spurred the development of alternatives. Sodium zirconium cyclosilicate (SZC) is a promising agent that selectively binds potassium in the gut and eliminates it, while being safe for chronic use based on 1 year of data. Even though we do not have head-to-head studies among the three currently available binders, SZC stands out in rapidity of onset and efficacy. Expert opinion In this review, we summarize the general management of hyperkalemia, including new agents. We review the pre-clinical and clinical data relating to sodium zirconium cyclosilicate.

引用

页码：1055 / 1064

页数：10

共 56 条

[1] Treatment of Severe Hyperkalemia: Confronting 4 Fallacies [J].

Abuelo, J. Gary .

KIDNEY INTERNATIONAL REPORTS, 2018, 3 (01) :47-55

[2] Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial [J].

Anker, Stefan D. ;

Kosiborod, Mikhail ;

Zannad, Faiez ;

Pina, Ileana L. ;

McCullough, Peter A. ;

Filippatos, Gerasimos ;

van der Meer, Peter ;

Ponikowski, Piotr ;

Rasmussen, Henrik S. ;

Lavin, Philip T. ;

Singh, Bhupinder ;

Yang, Alex ;

Deedwania, Prakash .

EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 (10) :1050-1056

[3] A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient [J].

Ash, Stephen R. ;

Singh, Bhupinder ;

Lavin, Philip T. ;

Stavros, Fiona ;

Rasmussen, Henrik S. .

KIDNEY INTERNATIONAL, 2015, 88 (02) :404-411

[4] Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease The AMETHYST-DN Randomized Clinical Trial [J].

Bakris, George L. ;

Pitt, Bertram ;

Weir, Matthew R. ;

Freeman, Mason W. ;

Mayo, Martha R. ;

Garza, Dahlia ;

Stasiv, Yuri ;

Zawadzki, Rezi ;

Berman, Lance ;

Bushinsky, David A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (02) :151-161

[5]

Beccari MV, 2017, CORE EVID, V12, P11, DOI 10.2147/CE.S129555

[6]

Bern DS, 2001, ASAIO J, V47, P151

[7]

Chaitman Martin, 2016, P T, V41, P43

[8] Secondary Prevention of Hyperkalemia With Sodium Polystyrene Sulfonate in Cardiac and Kidney Patients on Renin-Angiotensin-Aldosterone System Inhibition Therapy [J].

Chernin, Gil ;

Gal-Oz, Amir ;

Ben-Assa, Eyal ;

Schwartz, Idit F. ;

Weinstein, Talia ;

Schwartz, Doron ;

Silverberg, Donald S. .

CLINICAL CARDIOLOGY, 2012, 35 (01) :32-36

[9] Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes [J].

Collins, Allan J. ;

Pitt, Bertram ;

Reaven, Nancy ;

Funk, Susan ;

McGaughey, Karen ;

Wilson, Daniel ;

Bushinsky, David A. .

AMERICAN JOURNAL OF NEPHROLOGY, 2017, 46 (03) :213-221

[10] Dietary Approach to Recurrent or Chronic Hyperkalaemia in Patients with Decreased Kidney Function [J].

Cupisti, Adamasco ;

Kovesdy, Csaba P. ;

D'Alessandro, Claudia ;

Kalantar-Zadeh, Kamyar .

NUTRIENTS, 2018, 10 (03)

← 1 2 3 4 5 6 →